OptiNose (NASDAQ:OPTN) Stock Price Expected to Rise, HC Wainwright Analyst Says

OptiNose (NASDAQ:OPTN) had its price objective increased by HC Wainwright from $5.00 to $18.00 in a research report sent to investors on Friday, Marketbeat.com reports. HC Wainwright currently has a buy rating on the stock.

Separately, Piper Sandler cut their target price on shares of OptiNose from $45.00 to $15.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th.

OptiNose Stock Down 3.0 %

NASDAQ:OPTN opened at $6.50 on Friday. OptiNose has a 12-month low of $4.82 and a 12-month high of $31.50. The firm has a market capitalization of $980.39 million, a price-to-earnings ratio of -23.21 and a beta of -0.16. The stock’s 50 day moving average price is $7.81 and its two-hundred day moving average price is $11.86.

Hedge Funds Weigh In On OptiNose

Several institutional investors and hedge funds have recently modified their holdings of OPTN. FMR LLC boosted its holdings in OptiNose by 3.2% in the 3rd quarter. FMR LLC now owns 16,541,849 shares of the company’s stock valued at $11,083,000 after purchasing an additional 518,610 shares during the period. Great Point Partners LLC boosted its stake in shares of OptiNose by 56.2% in the second quarter. Great Point Partners LLC now owns 13,727,097 shares of the company’s stock valued at $14,276,000 after buying an additional 4,940,779 shares during the period. Nantahala Capital Management LLC grew its position in OptiNose by 442.3% during the second quarter. Nantahala Capital Management LLC now owns 13,418,740 shares of the company’s stock worth $14,425,000 after buying an additional 10,944,444 shares in the last quarter. Rosalind Advisors Inc. grew its position in OptiNose by 9.8% during the third quarter. Rosalind Advisors Inc. now owns 8,287,503 shares of the company’s stock worth $5,553,000 after buying an additional 740,355 shares in the last quarter. Finally, Stonepine Capital Management LLC increased its stake in OptiNose by 142.1% during the 3rd quarter. Stonepine Capital Management LLC now owns 5,688,590 shares of the company’s stock worth $3,811,000 after acquiring an additional 3,338,580 shares during the period. 85.60% of the stock is currently owned by institutional investors and hedge funds.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.